中核科技(000777.SZ):西北市場主要是石油化工、煤化工、煤電廠等項目,閥門需求量很大,市場前景廣闊
格隆匯5月24日丨中核科技(000777.SZ)於2023年5月23日14:00-15:00召開業績説明會,問答環節中,就“公司成立市場營銷西北分部在拓展渠道開發方面對公司未來發展的助益。”,公司回覆稱,公司成立市場營銷西北分部是對市場開發模式的探索,開發新項目、開發新市場和拓展銷售渠道,為其他重大區域設立銷售分部積累經驗。
市場營銷西北分部成立以來,在項目報備數量、市場信息獲取、渠道建設、訂單獲取等方面都取得了實質進展。從公司市場營銷西北分部近期的市場走訪情況看,西北市場主要是石油化工、煤化工、煤電廠等項目,閥門需求量很大,市場前景廣闊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.